VYLUMA ANNOUNCES POSITIVE RESULTS FROM SECOND STAGE OF PHASE III CHAMP STUDY OF NVK002 FOR THE TREATMENT OF MYOPIA IN CHILDREN
Vyluma announced today positive top-line results from the second stage of its Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study of its lead compound…
This link leads to the machine readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.
https://www.cigna.com/legal/compliance/machine-readable-files